Home > Insider Trading > Filing (0000904454-21-000844)

Filing Details

Accession Number:: 0000904454-21-000844
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-12-15 20:57:01
Reporting Period:: 2021-12-13

Accepted Time:: 2021-12-15 20:57:01
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1178711	Paratek Pharmaceuticals Inc.	PRTK	Pharmaceutical Preparations (2834)	330960223

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1788249	B. Randall Brenner	C/O Paratek Pharmaceuticals, Inc. 75 Park Plaza, 4Th Floor Boston MA 02116	Chief Development & Regulatory	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2021-12-13	4,479	$4.42	276,945	No	4	S	Direct
Common Stock	Disposition	2021-12-14	7,635	$4.37	269,310	No	4	S	Direct
Common Stock	Disposition	2021-12-15	15,780	$4.27	253,530	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $4.31 to $4.52. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $4.20 to $4.48. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $4.11 to $4.34. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 to this Form 4.